0001562180-24-001227.txt : 20240209 0001562180-24-001227.hdr.sgml : 20240209 20240209174327 ACCESSION NUMBER: 0001562180-24-001227 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MOORE JOHN R CENTRAL INDEX KEY: 0001191702 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 24616410 MAIL ADDRESS: STREET 1: 3200 WALNUT ST CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-262-7002 MAIL ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-02-07 false 0001710072 Edgewise Therapeutics, Inc. EWTX 0001191702 MOORE JOHN R C/O EDGEWISE THERAPEUTICS, INC. 1715 38TH STREET BOULDER CO 80301 false true false false General Counsel true Common Stock 2024-02-07 4 M false 17993.00 1.93 A 17993.00 D Common Stock 2024-02-07 4 S false 17993.00 20.0002 D 0.00 D Common Stock 2024-02-08 4 M false 3813.00 1.93 A 3813.00 D Common Stock 2024-02-08 4 S false 3813.00 20.0065 D 0.00 D Common Stock 2024-02-09 4 M false 8029.00 1.93 A 8029.00 D Common Stock 2024-02-09 4 S false 8029.00 20.0096 D 0.00 D Stock Option (Right to Buy) 1.93 2024-02-07 4 M false 17993.00 0.00 D 2030-12-15 Common Stock 17993.00 105004.00 D Stock Option (Right to Buy) 1.93 2024-02-08 4 M false 3813.00 0.00 D 2030-12-15 Common Stock 3813.00 101191.00 D Stock Option (Right to Buy) 1.93 2024-02-09 4 M false 8029.00 0.00 D 2030-12-15 Common Stock 8029.00 93162.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 30, 2023. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.15, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. /s/ John R. Moore 2024-02-09